List of Contributors

What is non-alcoholic fatty liver disease (NAFLD), and why is it important? p. 1
NAFLD in the community p. 17
Pathology of NAFLD p. 27
The natural history of NAFLD p. 37
Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH) p. 46
Diabetes and NAFLD: why is the connection important? p. 62
NAFLD and cardiovascular risk factors: implications for vascular disease p. 71
A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer p. 84
Imaging of NAFLD p. 93
Non-invasive methods to determine the severity of NAFLD and NASH p. 112
Fatigue, quality of life, and psychosocial issues for people with NAFLD p. 122
Physical activity and cardiovascular fitness in patients with NAFLD: clinical importance and therapeutic implications p. 132
NAFLD, obesity, and bariatric surgery p. 149
Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management p. 157
NAFLD in children p. 171
The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure p. 182
Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers p. 192
NAFLD in Chinese and South Asian people p. 206
Non-alcoholic fatty liver disease in Japan p. 217
Non-alcoholic fatty liver disease in South America and Hispanic people p. 228
Alcohol in non-alcoholic fatty liver disease: an oxymoron or a new standard of care? p. 234
Dietary factors in the pathogenesis and care of patients with fatty liver disease p. 248
Metabolic factors and steatosis in patients with hepatitis B and C p. 260
Drug therapy for NASH: insulin-sensitizing agents (metformin and thiazolidinediones) p. 271
Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines p. 284
Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents p. 293
Index p. 308
Color plate section facing p. 86

Table of Contents provided by Blackwell's Book Services and R.R. Bowker. Used with permission.